Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Severe Acute Respiratory Syndrome 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mastocytosis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Hairy Cell 1Leukemia 1Hypersensitivity 1Hodgkin Disease 1Gliosarcoma 1Glioblastoma 1Fatigue 1Colorectal Neoplasms 1COVID-19 1

Interventions

Temozolomide 31Radiotherapy 25Magnetic Resonance Spectroscopy 17Radiation 13Surgical Procedures, Operative 12Specimen Handling 9Radiotherapy, Conformal 9Bevacizumab 9Immunoglobulin G 8Disulfides 8Carmustine 8Vorinostat 7Radiotherapy, Intensity-Modulated 7Erlotinib Hydrochloride 7Chemotherapy, Adjuvant 7temsirolimus 6cediranib 6Sirolimus 6motexafin gadolinium 5Sorafenib 5Nivolumab 5Cilengitide 5Carboplatin 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5tipifarnib 4Lapatinib 4Congresses as Topic 4veliparib 3Procarbazine 3O(6)-benzylguanine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Glioblastoma × Sodium Chloride × Clear all
NCT04216329 2026-01-23

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

National Institutes of Health Clinical Center (CC)

Phase 1 Active not recruiting
11 enrolled 19 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡